Zacks Investment Research downgraded shares of XOMA CORP (XOMA) from OUTPERFORM to NEUTRAL on February 08, 2012, with a target price of $1.80.
XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on XOMA CORP (XOMA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment